A Single-Center, Double-Blind Placebo Controlled Study to Evaluate the Efficacy of Kre-Celazine ® , an Oral Buffered Creatine- Cetylated Fatty Acid Compound, in its Ability to Reduce Site-specific Inflammation and Pain

In order to determine whether an oral, alkali bufferedcreatine – cetylated fatty acid compound was capable of reducing site-specific chronic joint and muscle related inflammation/pain with equal effectiveness, 35 subjects, each fulfilling the entrance criteria, were divided into 2 groups – Group A (“Test Compound” group) and Group B (“Placebo group”). Each participant took the same number of capsules irrespective of their group assignment, for 30 consecutive days. Efficacy was based on the final evaluation of pre and post blood tests, physical examinations (entrance and exit) and participants’ “Pain Journal” comments. Results indicated that approximately 100% of ankle/foot pain, 80 - 85% of neck/ shoulder/elbow/wrist and hand pain, 71% of knee pain, respondents in Group A rated their “compound” better than/as good as a prescription product in its ability to reduce/eliminate pain. Hip and back pain scores for Group A were no better than placebo scores. Group A experienced a modest increase in mobility (35%), but no measurable increase in range of motion over and above that experienced in Group B. The alkali buffered-creatine – cetylated fatty acid compound exerted its greatest impact on areas of inflammation/pain in the extremities, as well as in the neck and shoulder region.